soleno
therapeutics
announces
updated
results
phase
iii
trial
dccr
treatment
syndrome
updated
results
demonstrate
significant
dccr
exposure
response
relationship
interim
analysis
extension
data
demonstrate
continued
efficacy
improvements
body
composition
metabolic
measures
support
efficacy
dccr
treatment
pws
symptoms
redwood
city
globe
newswire
soleno
therapeutics
soleno
nasdaq
slno
biopharmaceutical
company
developing
novel
therapeutics
treatment
rare
diseases
today
announced
updated
results
company
phase
iii
trial
destiny
pws
evaluating
diazoxide
choline
controlled
release
dccr
tablets
patients
syndrome
pws
highlighted
oral
presentation
jennifer
miller
professor
division
pediatric
endocrinology
university
florida
foundation
research
annual
research
symposium
destiny
pws
randomized
phase
iii
study
oncedaily
oral
administration
dccr
pws
patients
conducted
sites
objective
study
assess
efficacy
safety
dccr
subjects
ages
four
years
older
pws
patients
completed
study
enrolled
study
ongoing
extension
study
soleno
previously
announced
initial
results
destiny
pws
june
study
meet
primary
endpoint
change
baseline
hyperphagia
measured
total
score
hyperphagia
questionnaire
clinical
trials
however
significant
changes
observed
two
three
key
secondary
endpoints
improvement
physician
assessed
clinical
global
impression
improvement
score
reduction
body
fat
mass
subjects
receiving
dccr
compared
placebo
interim
analysis
subset
patients
completed
weeks
treatment
showed
continued
improvement
hyperphagia
well
several
pws
related
behaviors
key
updated
results
significant
exposure
response
relationship
dccr
plasma
concentrations
change
baseline
score
observed
analyses
treatment
windows
revealed
continued
efficacy
dccr
time
compared
worsening
effects
placebo
larger
decrease
baseline
week
placebo
compared
dccr
subjects
week
end
study
placebo
subjects
worsened
dccr
subjects
continued
improve
significant
improvements
dccr
compared
placebo
observed
leptin
adiponectin
adipokines
differentially
expressed
obesity
cardiovascular
diseases
leptin
levels
elevated
obesity
due
increased
body
fat
mass
leptin
resistance
adiponectin
levels
downregulated
obesity
dccr
led
decrease
leptin
levels
compared
increase
placebo
p
dccr
led
increase
adiponectin
levels
compared
placebo
p
significant
improvements
measures
observed
significant
reductions
baseline
fasting
insulin
levels
dccr
compared
placebo
observed
week
week
week
treatment
dccr
resulted
significant
improvement
insulin
resistance
measured
using
homeostatic
model
assessment
insulin
resistance
compared
placebo
interim
analysis
change
baseline
week
extension
study
indicated
nearly
subjects
treated
dccr
showed
improvement
score
median
baseline
score
compared
median
week
score
reduction
demonstrating
continued
improvement
improvement
various
pws
related
behaviors
anxiety
rigidity
compulsivity
aggression
etc
seen
dccr
treatment
safety
profile
dccr
remains
consistent
known
safety
profile
diazoxide
prior
experience
dccr
serious
unexpected
reportable
adverse
events
reported
dccr
program
date
patients
continue
treated
dccr
treated
year
results
program
continue
demonstrate
dccr
beneficial
impact
hyperphagia
predominant
symptom
pws
behaviors
typical
pws
well
problems
related
body
composition
safety
profile
well
understood
said
miller
principal
investigator
soleno
study
sum
total
data
presented
date
suggest
dccr
approved
may
safe
effective
treatment
option
address
behavioral
metabolic
components
pws
look
forward
continued
progress
advancing
dccr
first
potentially
approved
treatment
key
unmet
needs
associated
pws
devastating
condition
compelling
updated
data
bolster
confidence
dccr
safety
efficacy
profile
pws
said
anish
bhatnagar
chief
executive
officer
soleno
therapeutics
continue
treat
patients
study
extension
previously
communicated
expect
meet
food
drug
administration
determine
next
steps
potential
path
forward
address
unmet
need
safe
effective
treatment
option
pws
dccr
orphan
designation
treatment
pws
eu
fast
track
designation
food
drug
administration
pws
syndrome
association
usa
estimates
one
people
pws
hallmark
symptom
disorder
hyperphagia
chronic
feeling
insatiable
hunger
severely
diminishes
quality
life
pws
patients
families
additional
characteristics
pws
include
behavioral
problems
cognitive
disabilities
low
muscle
tone
short
stature
treated
growth
hormone
accumulation
excess
body
fat
developmental
delays
incomplete
sexual
development
hyperphagia
lead
significant
morbidities
stomach
rupture
obesity
diabetes
cardiovascular
disease
mortality
choking
accidental
death
due
food
seeking
behavior
global
survey
conducted
foundation
research
respondents
parent
caregivers
rated
hyperphagia
important
important
symptom
relieved
new
medicine
currently
approved
therapies
treat
hyperphagia
appetite
metabolic
cognitive
function
behavioral
aspects
disorder
diazoxide
choline
received
orphan
drug
designation
treatment
pws
eu
fast
track
designation
diazoxide
choline
dccr
tablet
diazoxide
choline
tablet
novel
proprietary
crystalline
salt
formulation
diazoxide
administered
parent
molecule
diazoxide
used
decades
thousands
patients
rare
diseases
neonates
infants
children
adults
approved
use
pws
soleno
conceived
established
extensive
patent
protection
therapeutic
use
diazoxide
dccr
patients
pws
dccr
development
program
supported
data
five
completed
phase
clinical
studies
healthy
volunteers
three
completed
phase
ii
clinical
studies
one
pws
patients
pws
phase
ii
study
dccr
showed
promise
addressing
hyperphagia
hallmark
symptom
pws
well
several
symptoms
aggressive
destructive
behaviors
fat
mass
metabolic
parameters
soleno
therapeutics
soleno
focused
development
commercialization
novel
therapeutics
treatment
rare
diseases
company
lead
candidate
diazoxide
choline
dccr
tablets
oral
tablet
treatment
syndrome
pws
currently
evaluated
phase
iii
clinical
development
program
information
please
visit
statements
press
release
contains
statements
within
meaning
section
securities
exchange
act
amended
statements
statements
historical
facts
contained
press
release
statements
including
statements
regarding
timing
regulatory
process
ultimate
approvals
determining
path
forward
dccr
treatment
pws
impact
pandemic
operations
clinical
trial
cases
identify
statements
terms
may
expect
plan
anticipate
could
intend
target
project
contemplates
believes
estimates
predicts
potential
continue
negative
terms
similar
expressions
statements
speak
date
press
release
subject
number
risks
uncertainties
assumptions
including
risks
uncertainties
associated
market
conditions
well
risks
uncertainties
inherent
soleno
business
including
described
company
prior
press
releases
periodic
reports
files
sec
events
circumstances
reflected
company
statements
may
achieved
occur
actual
results
could
differ
materially
projected
statements
except
required
applicable
law
company
plan
publicly
update
revise
statements
contained
herein
whether
result
new
information
future
events
changed
circumstances
otherwise
corporate
contact
brian
ritchie
lifesci
advisors
llc
